Defibrillator News and Research

Latest Defibrillator News and Research

Cedars-Sinai’s first patient implanted with SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc., manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, said today that Cedars-Sinai Medical Center in Los Angeles has discharged its first patient to be implanted with the SynCardia temporary Total Artificial Heart.

11 May 2012

PET imaging for sudden cardiac arrest can identify candidates for ICDs

New research from the University at Buffalo suggests that cardiologists may have a new way to identify patients who are at the highest risk of sudden cardiac arrest, and the most likely to benefit from receiving an implantable cardiac defibrillator (ICD).

11 May 2012

ICD therapy significantly reduces mortality in patients with moderate heart failure

St. Jude Medical, Inc., a global medical device company, today announced results of the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) 10-Year Follow-up Study at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston. The study demonstrated implantable cardioverter defibrillator (ICD) therapy significantly reduces mortality for at least 11 years in patients with moderate heart failure (HF).

11 May 2012

FDA approves St. Jude Medical’s Ellipse ICD

St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of its Ellipse implantable cardioverter defibrillator (ICD).

10 May 2012

FDA approves St. Jude Medical's Assura family of implantable defibrillators

St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of its Assura portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds).

8 May 2012

CINJ nurses develop new teaching method to improve patient safety

Oncology nurses in the outpatient setting face constant challenges in the management of patient care, as many cancer patients receive therapies known to cause allergic reactions or hypersensitivity. When such emergencies arise, oncology nurses need to quickly, competently and safely manage these specific needs. In order to address such a scenario, nurses at The Cancer Institute of New Jersey (CINJ) have developed a teaching method to make mock situations more closely resemble real emergency events.

5 May 2012

CR2 announces acquisition of CardioReady

CR2, LLC announced the acquisition of CardioReady, a pioneer in Cardiac Emergency Response and Automated External Defibrillator (AED) deployment since 2004. Using a patented suite of solutions, CardioReady assists organizations across the United States in protecting the lives of their customers, employees, and other visitors to their sites against Sudden Cardiac Arrest (SCA) – the leading cause of death in America.

30 Apr 2012

Potential hazards of performing MRI in patients with cardiac pacemaker

Great care should be taken when performing magnetic resonance imaging (MRI) in patients with a cardiac pacemaker. Henning Bovenschulte and his co-authors review recent findings in the latest issue of Deutsches Ärzteblatt International.

30 Apr 2012

FDA approves Spectranetics' advanced GlideLight Laser Sheath

The Spectranetics Corporation today announced FDA approval of the new advanced GlideLight Laser Sheath for removal of cardiac leads. As part of the company's vision to safely manage every lead, GlideLight delivers more precise control to reduce the force for safe lead extraction.

26 Apr 2012

St. Jude Medical's Ellipse ICD receives CE Mark Approval

St. Jude Medical, Inc., a global medical device company, today announced CE Mark Approval of the Ellipse implantable cardioverter defibrillator (ICD). Designed with feedback from more than 200 physicians from around the world, the Ellipse ICD provides the benefits of advanced features and power in the industry's smallest high-energy ICD.

16 Apr 2012

FDA approves Medtronic’s expanded indication for implantable CRT-D devices

Medtronic, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for its cardiac resynchronization therapy with implantable cardioverter defibrillator (CRT-D) devices.

From Medtronic 11 Apr 2012

Heart Rhythm Journal manuscript by Dr. Hauser inaccurate and biased, says St. Jude Medical

St. Jude Medical, Inc., a global medical device company, today announced it is seeking a retraction of the manuscript accepted for publication in the Heart Rhythm Journal by Dr. Robert Hauser, et al., titled, "Deaths Caused by the Failure of Riata and Riata ST Implantable Cardioverter-Defibrillator Leads."

7 Apr 2012

TYRX enrolls 1000th patient in CITADEL/CENTURION AIGISRx Antibacterial Envelope studies

TYRX, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with cardiovascular implantable electronic devices (CIEDs), announced today that the 1000th patient has been enrolled into the CITADEL & CENTURION clinical studies evaluating the company's AIGISRx Antibacterial Envelope.

2 Apr 2012

New CMS requirement increases ICD placement costs

The cost to place an implantable cardioverter-defibrillator (ICD) increased by $844 per case after a new requirement from the Centers for Medicare and Medicaid Services (CMS) went into effect in February 2010, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

CRT-D appropriate for patients with left ventricular dysfunction

Cardiac resynchronization therapy with defibrillators (CRT-D) is appropriate for patients who have left ventricular dysfunction and require chronic ventricular pacing, based on the findings of an observational study that being presented March 26 that the 61st annual American College of Cardiology (ACC) scientific session.

27 Mar 2012

Lower BMI increases risk during insertion of ICDs

Patients who are underweight or small in stature are twice as likely to experience complications or die during insertion of an implantable cardioverter-defibrillator (ICD) compared to obese and normal-weight patients, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

26 Mar 2012

UM, Shock Trauma partner to train dental students, residents

The University of Maryland's (UM) School of Dentistry has teamed up with the UM School of Medicine's R Adams Cowley Shock Trauma Center for training future dentists to respond efficiently and effectively to life threatening medical emergencies in a dental setting.

16 Mar 2012

Asahi Kasei to acquire ZOLL

Asahi Kasei Corporation, and ZOLL Medical Corporation today jointly announced that Asahi Kasei, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, has entered into a definitive merger agreement with ZOLL, a manufacturer of resuscitation and critical care devices and related software solutions, pursuant to which Asahi Kasei will acquire ZOLL for approximately $2.21 billion.

12 Mar 2012

Boston Scientific in bid to take over Cameron Health

Boston Scientific, the second-biggest cardiac-device maker, will pay $150 million when the deal closes and another $150 million if Cameron’s technology called the S-ICD System wins U.S. Food and Drug Administration approval, the Natick, Massachusetts-based company said in a statement yesterday.

12 Mar 2012

Boston Scientific exercises option to acquire Cameron Health

Boston Scientific Corporation announces the exercise of its option to acquire Cameron Health, Inc., a privately held company based in San Clemente, California.

9 Mar 2012